COCHEnvoy Medical, Inc.
This year, Envoy Medical has to prove it can turn around its financial performance and rekindle investor confidence — and the next catalyst is a shareholder vote on a 1-for-News corporate action on 2026-10-12, with a modeled bull path to $0.80 and a bear fallback to $0.68, leaning bullish at 55%. If the vote passes, it could signal a shift in corporate direction, but if it fails, the stock may struggle to hold its ground. The path forward is clear: earnings reports in November, February, May, and August will test the company’s ability to deliver consistent results, and each one will be a new opportunity — or a warning sign — for the stock.
The Read
After missing revenue estimates in Q2 2026, Envoy Medical's stock rallied 8%.
The schedule
- Mon12Oct
Shareholder vote on a 1-for-News corporate action.
- Mon9Nov
Quarterly earnings report with revenue and guidance.
- Sun14Feb
- Mon3May
- Mon9Aug
Past
- Mon10Aug
Actual outcome: Bull · $0.75 at outcome
Envoy Medical reported a quarterly loss of $0.07 per share, matching the estimate, but provided positive regulatory and clinical updates, including submission of the first module of its PMA application to the FDA and positive 12-month Stage 1 data. These developments signaled progress in the regulatory process and clinical performance, driving the stock higher despite the EPS miss.
- Mon11May
Actual outcome: Bear · $0.63 at outcome
Price reached or fell below bear floor ($0.48) at outcome date.